cobas® SARS-CoV-2

Fast, trusted SARS-CoV-2 PCR results, to enable informed care decisions

cobas® SARS-CoV-2
Help prevent the silent spread of SARS-CoV-2

SARS-CoV-2 may be difficult for clinicians to identify on symptoms alone. Many patients may be asymptomatic and if left undiagnosed, it may result in health complications or community spread.

With nearly 3.6 million deaths and nearly 171 million cases1 of COVID-19 reported so far worldwide, effective tools are needed to deliver rapid results to identify symptomatic and asymptomatic individuals.

cobas® SARS-CoV-2 is the first real-time polymerase chain reaction (PCR) test that provides targeted identification within 20 minutes for both asymptomatic and symptomatic persons, enabling informed decisions at the point of care.

Relying on the rapid and accurate cobas® SARS-CoV-2 performance, healthcare providers now have the urgent answers they need to rule-in or rule-out SARS-CoV-2.


cobas® SARS-CoV-2 Performance*


Symptomatic individuals


LOD: 2.4 x 10-2 TCID 50/mL
(24 copies/mL)

Positive Agreement**

Symptomatic Positive 96.1

(95% CI: 89.0%-98.6%)

Negative Agreement**

Symptomatic Negative 96.8

(95% CI: 92.6%-98.6%)

Asymptomatic individuals

LOD: 1.2 x 10-2 TCID 50/mL

Positive Agreement**

Asymptomatic Positive 100

(95% CI: 84.5%-100%)

Negative Agreement**

Asymptomatic Negative 98.9

(95% CI: 96.2%-99.7%)

* cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® liat system, Package Insert V01, Pleasanton, CA; Roche Molecular Systems, Inc., 2021.
** Compared to FDA EUA SARS-CoV-2 RT-PCR assays; IFU data.   
CI=confidence intervals. LOD=limit of detection.  TCID=tissue culture infective dose.

Learn more about the expanding menus of assays

cobas® liat system


Rapidly test, triage, and treat your patients with the accuracy, simplicity, and security needed at the point of care.

Learn more
360 Logo Drag Image to Rotate
360 degree images list
Do you have any questions?
Contact us
Intended Use

Intended Use

The cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® liat system (cobas® SARS-CoV-2) is an automated real-time RT-PCR assay intended for the rapid in vitro qualitative detection of nucleic acid from SARS-CoV-2 in self-collected anterior nasal (nasal) swabs (collected in a healthcare setting with instruction by a healthcare provider) and healthcare provider-collected nasopharyngeal, mid-turbinate and anterior nasal (nasal) swabs from either individuals suspected of COVID-19 by their healthcare provider or from any individual, including individuals without symptoms or other reasons to suspect COVID-19.

Results are for the identification of SARS-CoV-2 nucleic acids. SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA. Positive results do not rule out bacterial infection or co-infection with other viruses. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and/or epidemiological information.

cobas® SARS-CoV-2 is intended for use by health professionals or trained operators who are proficient in using the cobas® liat system.

In the United States (US), testing with cobas® SARS-CoV-2 is authorized for laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate or high complexity tests. cobas® SARS-CoV-2 is also authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Laboratories within the U.S. and its territories are required to report all SARS-CoV-2 results to the appropriate public health authorities.

In the U.S., cobas® SARS-CoV-2 is only for use under the Food and Drug Administration’s Emergency Use Authorization."

FDA Emergency Use Authorization (EUA)

The cobas® liat system is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Access package inserts through your country’s Roche Diagnostics Website.

young girls diagnosed with influenza

Test for it. Don’t ignore it.


1., Last accessed 3 Jun 21

cobas® SARS-CoV-2 assay specifications

  • Instrument

    cobas® liat system

  • Target


  • Sample type

    Nasopharyngeal swab, nasal swab, mid-turbinate swab

  • Collection media

    Universal Transport Media (UTM), 0.85 & 0.9% saline

  • Sample extraction

    Fully automated and integrated

  • Technology

    Real-time PCR

  • Control

    Internal sample processing control, positive and negative controls

  • Time to result

    ~20 minutes

  • Reagents

    Ready-to-use, pre-packed tube format

  • Kit Storage


  • Registration

    Emergency Use Authorization (EUA); CE-IVD